Product Information
TRILEPTAL 300 MG/5 ML SUSP is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $1.9308 per ML under NDC 00078035752. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on May 25, 2001. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the oxcarbazepine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
60 mg/mL
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078035752
Classification
Brand
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OXCARBAZEPINEApproval Type
New Drug (NDA)
FDA Application
NDA021285FDA Approved
5/25/2001
TE Code
AB
On Market Since
5/30/2001
Pharmacological Classes
Price Statistics
The NADAC for TRILEPTAL 300 MG/5 ML SUSP has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 124.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9308 per ML |
|---|---|
| All-time high | $1.9345 (May 13, 2026) |
| All-time low | $0.8587 (Nov 28, 2013) |
| 52-week high | $1.9345 |
| 52-week low | $1.8759 |
| Median price | $1.5409 |
| Average price | $1.5136 |
| Largest weekly change | +14.9% (Jan 14, 2015) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the oxcarbazepine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novartis Pharmaceuticals Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
oxcarbazepine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-epileptic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRILEPTAL 300 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for TRILEPTAL 300 MG/5 ML SUSP, manufactured by Novartis Pharmaceuticals Corporation, is $1.9308 per ML (NDC 00078035752), effective Sep 30, 2026.
How has the price of TRILEPTAL 300 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for TRILEPTAL 300 MG/5 ML SUSP has risen 124.8%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TRILEPTAL 300 MG/5 ML SUSP?
Since Nov 28, 2013, the NADAC for TRILEPTAL 300 MG/5 ML SUSP has ranged from a low of $0.8587 (Nov 28, 2013) to a high of $1.9345 (May 13, 2026), with a median of $1.5409 per ML.
Are there cheaper alternatives to TRILEPTAL 300 MG/5 ML SUSP?
No other NADAC-published product currently shares the active ingredient and strength of TRILEPTAL 300 MG/5 ML SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TRILEPTAL 300 MG/5 ML SUSP?
TRILEPTAL 300 MG/5 ML SUSP (NDC 00078035752) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.